文献速递前列腺癌

局限性前列腺癌行前列腺切除术、近距离放疗、外照射放疗、激素治疗或监测后的长期前列腺癌特异性死亡率

Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
PubMed 文献 · Eur Urol · 2023-10-17

这项基于多中心前瞻性CaPSURE注册队列的研究纳入11864例局限性前列腺癌男性,比较根治性前列腺切除术、近距离放疗、外照射放疗、原发性雄激素剥夺治疗或监测后的长期生存。中位随访9.4年,调整CAPRA评分后,以根治性前列腺切除术为参照,其他治疗的前列腺癌特异性死亡风险均更高;低危疾病中差异可忽略,风险越高差异越明显。

要点

  • 中位随访9.4年,11864例中764例死于前列腺癌。
  • 以根治性前列腺切除术为参照,近距离放疗、外照射放疗、原发性雄激素剥夺治疗和监测的前列腺癌特异性死亡风险均更高。
  • 前列腺癌特异性死亡差异在低危疾病中可忽略,并随风险升高而逐渐增大。

核心结论

  • 在大型前瞻性局限性前列腺癌队列中,调整年龄和合并症后,较高危疾病患者接受局部治疗后前列腺癌特异性死亡率较低,尤其是根治性前列腺切除术。
  • 等待正在进行的试验的长期随访来确认这些结果。

研究设计与样本

  • 多中心、前瞻性、以社区为基础的癌症前列腺战略泌尿学研究卓越(CaPSURE)注册队列研究,长期随访。
  • 纳入活检证实、临床T1-3aN0M0局限性前列腺癌男性,诊断后6个月内连续入组,具备临床风险数据且诊断后至少12个月随访。
  • 共11864例男性:6227例(53%)接受根治性前列腺切除术,1645例(14%)接受近距离放疗,1462例(12%)接受外照射放疗,1510例(13%)接受原发性雄激素剥夺治疗,1020例(9%)接受主动监测/观察等待。

主要发现

  • 中位随访9.4年(四分位距5.8-13.7年)后,764例男性死于前列腺癌。
  • 调整CAPRA评分后,以根治性前列腺切除术为参照,前列腺癌特异性死亡的风险比为:近距离放疗1.57(95%CI 1.24-1.98;p<0.001),外照射放疗1.55(95%CI 1.26-1.91;p<0.001),原发性雄激素剥夺治疗2.36(95%CI 1.94-2.87;p<0.001),主动监测/观察等待1.76(95%CI 1.30-2.40;p<0.001)。
  • 在长期结局模型中,低危疾病的前列腺癌特异性死亡差异可忽略,并随风险升高而逐渐增大。

局限性

  • 局限性包括前列腺癌诊断和治疗策略随时间演变。
  • 在这项非随机研究中,残余混杂的可能性仍然突出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment of localized prostate cancer (PCa) remains controversial. OBJECTIVE: To compare long-term survival among men who underwent radical prostatectomy (RP), brachytherapy (BT), external beam radiation therapy (EBRT), primary androgen deprivation therapy (PADT), or monitoring (active surveillance [AS]/watchful waiting [WW]) for PCa. DESIGN, SETTING, AND PARTICIPANTS: This is a cohort study with long-term follow-up from the multicenter, prospective, largely community-based Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry. Men with biopsy-proven, clinical T1-3aN0M0, localized PCa were consecutively accrued within 6 mo of diagnosis and had clinical risk data and at least 12 mo of follow-up after diagnosis available. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PCa risk was assessed, and multivariable analyses were performed to compare PCa-specific mortality (PCSM) and all-cause mortality by primary treatment, with extensive adjustment for age and case mix using the Cancer of the Prostate Risk Assessment (CAPRA) score and a well-validated nomogram. RESULTS AND LIMITATIONS: Among 11 864 men, 6227 (53%) underwent RP, 1645 (14%) received BT, 1462 (12%) received EBRT, 1510 (13%) received PADT, and 1020 (9%) were managed with AS/WW. At a median of 9.4 yr (interquartile range 5.8-13.7) after treatment, 764 men had died from PCa. After adjusting for CAPRA score, the hazard ratios for PCSM with RP as the reference were 1.57 (95% confidence interval [CI] 1.24-1.98; p < 0.001) for BT, 1.55 (95% CI 1.26-1.91; p < 0.001) for EBRT, 2.36 (95% CI 1.94-2.87; p < 0.001) for PADT, and 1.76 (95% CI 1.30-2.40; p < 0.001) for AS/WW. In models for long-term outcomes, PCSM differences were negligible for low-risk disease and increased progressively with risk. Limitations include the evolution of diagnostic and therapeutic strategies for PCa over time. In this nonrandomized study, the possibility of residual confounding remains salient. CONCLUSIONS: In a large, prospective cohort of men with localized PCa, after adjustment for age and comorbidity, PCSM was lower after local therapy for those with higher-risk disease, and in particular after RP. Confirmation of these results via long-term follow-up of ongoing trials is awaited. PATIENT SUMMARY: We evaluated different treatment options for localized prostate cancer in a large group of patients who were treated mostly in nonacademic medical centers. Results from nonrandomized trials should be interpret with caution, but even after careful risk adjustment, survival rates for men with higher-risk cancer appeared to be highest for patients whose first treatment was surgery rather than radiotherapy, hormones, or monitoring.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Herlemann A, Cowan JE, Washington SL, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur Urol. 2023. PMID: 37858454. doi:10.1016/j.eururo.2023.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。